NCT03389035View on ClinicalTrials.gov

Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

March 31, 2021

Study Completion Date

December 30, 2022

Conditions

Acute Lymphoblastic Leukemia, in Relapse

Interventions

BIOLOGICAL

CARCIK-CD19

Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene

Trial Locations (2)

20900

Fondazione MBBM, Monza

24127

Ospedale PG23, Bergamo

All Listed Sponsors

lead

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

OTHER

NCT03389035 - Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT | Biotech Hunter | Biotech Hunter